TY - JOUR
T1 - Is gemcitabine cost effective in cancer treatment?
AU - Toschi, Luca
AU - Finocchiaro, Giovanna
AU - Ceresoli, Giovanni Luca
AU - Zucali, Paolo Andrea
AU - Cavina, Raffaele
AU - Garassino, Isabella
AU - De Vincenzo, Fabio
AU - Santoro, Armando
AU - Cappuzzo, Federico
PY - 2007/6
Y1 - 2007/6
N2 - Gemcitabine is a novel pyrimidine nucleoside antimetabolite agent that is active, either as monotherapy or in association with other cytotoxic compounds, in pancreatic, ovarian breast, bladder and non-small-cell lung cancer. The drug has an acceptable toxicity profile with myelosuppression being the most common adverse event. Pharmacoeconomic assessments have been performed in order to determine whether gemcitabine is a cost effective cancer treatment. Several cost analyses have investigated gemcitabine in association with cisplatin in the treatment of non-small-cell lung cancer, indicating that the combination is cost effective when compared with either old- or new-generation platinum-based treatments. Results in other malignancies are not corroborated by the same quality of evidence, therefore more extensive analyses are warranted. Overall, available data indicate that accurate selection of patients and careful cost analyses should be included in the development of new anticancer drugs for an appropriate use of limited healthcare resources.
AB - Gemcitabine is a novel pyrimidine nucleoside antimetabolite agent that is active, either as monotherapy or in association with other cytotoxic compounds, in pancreatic, ovarian breast, bladder and non-small-cell lung cancer. The drug has an acceptable toxicity profile with myelosuppression being the most common adverse event. Pharmacoeconomic assessments have been performed in order to determine whether gemcitabine is a cost effective cancer treatment. Several cost analyses have investigated gemcitabine in association with cisplatin in the treatment of non-small-cell lung cancer, indicating that the combination is cost effective when compared with either old- or new-generation platinum-based treatments. Results in other malignancies are not corroborated by the same quality of evidence, therefore more extensive analyses are warranted. Overall, available data indicate that accurate selection of patients and careful cost analyses should be included in the development of new anticancer drugs for an appropriate use of limited healthcare resources.
KW - Chemotherapy
KW - Gemcitabine non-small-cell lung cancer
KW - Pharmacoeconomics
UR - http://www.scopus.com/inward/record.url?scp=34547602958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547602958&partnerID=8YFLogxK
U2 - 10.1586/14737167.7.3.239
DO - 10.1586/14737167.7.3.239
M3 - Article
C2 - 20528311
AN - SCOPUS:34547602958
VL - 7
SP - 239
EP - 249
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
SN - 1473-7167
IS - 3
ER -